Phase 2 Clinical Trial Progress Update

Summary by AI BETAClose X

CRISM Therapeutics Corporation has announced significant progress in its Phase 2 clinical trial for irinotecan ChemoSeed® in glioblastoma patients, with all manufacturing, quality, regulatory, and start-up activities completed and site activation advanced. A Site Initiation Visit is planned for late July, after which patient recruitment and dosing updates will be provided. The company confirms it is fully funded to complete Part 1 of the trial and is well-positioned to commence Part 2.

Disclaimer*

UK 100

Latest directors dealings